Abstract:Objective To evaluate the effectiveness of terazosin, tamsulosin and fin asteride for benign prostatic hyperplasia (BPH). Methods We searched the related original studies all over the world , and only included randomized controlled trials (RCT) and quasi-randomized con trolled trials (CCT). MEDLINE (1966Dec. 2004), EMBASE (1984Dec . 2004), The Cochrane Library (Issue 4, 2004) and four Chinese databases were electronically searched and 10 related journals were handsearched . The studies included in the references of eligible studies were additionally searched. Two reviewers independently screened the studies for eligibility, eva luated the quality and extracted the data from the eligible studies, with confir mation by cross-checking. Divergences of opinion were consulted by a third part y. Meta-analysis was performed by using RevMan 4.2 software. Results Twelve original studies involving 2 471 participants met inclusion criteria. Compared with terazosin, tamsulosin could improve inter national prostatic symptom score, with WMD 0.75, 95% confidence interval (CI) 0.03 to 1 .46, P=0.04. There was no statistical difference between teraz osin and tamsulosin in improving the average rate of urine flow (WMD 0.23, 95%C I -0.39 to 0.85, P= 0.46), the residual urine volume (WMD 0.82, 95%CI -2.92 to 4.57, P =0.67) and in diminishing the volume of prostate (WMD=2.20, 95%CI -3 .99 to 8.39, P=0.49). There was no statistical difference bet ween finasteride and tamsulosin in improving the international prostatic symptom score (WMD 0.65, 95%CI -0.45 to 1.75, P=0.25) or the max r ate of urine flow (WMD 0.39, 95%CI -0.72 to 1.51, P=0.49). Only two studies compared finasteride with terazosin and had different conclusio ns. Only one study compared finasteride or terazosin with a combination of these drugs suggested that the combination had higher effective power than finasterid e alone but no difference with terazosin alone. Conclusions Although the effectiveness in some aspects is higher in the tamsul osin group, there is not enough evidence to show which one is the best among the se three drugs. The combination of finasteride and terazosin does not show more effectiveness than terazosin alone. This review suggests that tamsulosin alone s hould be used for the treatment of BPH and the combination needs to be identifie d by better evidence. It is important to improve the quality of original studies .

Comparing monotherapy with tadalafil or tamsulosin in men with benign prostatic hyperplasia: A case-control study

Comparative study of tamsulosin versus tadalafil in benign prostatic hyperplasia patients with lower urinary tract symptoms. A prospective randomized study

A comparative study of two means of simultaneous treatment for benign prostate hyperplasia and bladder stone

A Comparative Study on the Safety and Efficacy of Tamsulosin and Alfuzosin in the Management of Symptomatic Benign Prostatic Hyperplasia: A Randomized Controlled Clinical Trial

Efficacy of Low Daily Dose of Tadalafil as Mono-Therapy for Diabetic Patients With Lower Urinary Tract Symptoms Suggestive of Benign Enlargement of Prostate

Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia in men with or without erectile dysfunction

The efficacy of vardenafil and tamsulosin in treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: A randomised clinical trial

A Systematic Review and Meta-Analysis of the Efficacy and Safety of Tamsulosin Plus Tadalafil Compared With Tamsulosin Alone in Treating Males With Lower Urinary Tract Symptoms Secondary to Benign Prostrate Hyperplasia

Pharmacoeconomic Evaluation of Tamsulosin Hydrochloride Sustained-release Capsules in the Treatment of Benign Prostatic Hyperplasia

The comparison between finasteride and tamsulosin therapeutic efficacy in the treatment of symptomatic benign prostate hyperplasia

Tadalafil versus tamsulosin as combination therapy with 5-alpha reductase inhibitors in benign prostatic hyperplasia, urinary and sexual outcomes

Efficacy and Safety of 12-week Monotherapy With Once Daily 5 mg Tadalafil for Lower Urinary Tract Symptoms of Benign Prostatic Hyperplasia: Evidence-based Analysis

Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study

Efficacy And Safety Of Tadalafil 5 Mg Once-Daily In Asian Men With Both Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia And Erectile Dysfunction: A Phase 3, Randomized, Double-Blind, Parallel, Placebo- And Tamsulosin-Controlled Study

Observation on Curative Efficacy of Tamsulosin Hydrochloride Sustained-Release Capsules Combined with Finasteride Tablets in the Treatment of Benign Prostatic Hyperplasia

Evaluation of the Effectiveness of Terazosin, Tamsulosin a nd Finasteride for Benign Prostatic Hyperplasia

Comparison of Different Drugs on the Treatment of Benign Prostate Hyperplasia

The role of Tadalafil in the treatment of benign prostatic hyperplasia and erectile dysfunction

Tamsulosin Versus Terazosin for Benign Prostatic Hyperplasia: A Systematic Review

Effects of Tamsulosin Combined with Solifenacin on Lower Urinary Tract Symptoms: Evidence from a Systematic Review, Meta-Analysis, and Trial Sequential Analysis of Randomized Controlled Trials.

Tamsulosin versus terazosin for benign prostatic hyperplasia: a systematic review.